Market Overview

UPDATE: Credit Suisse Upgrades St. Jude Medical to Outperform on Durata Outlook

Related STJ
UPDATE: St. Jude Posts Upbeat Q3 Earnings, Lowers Forecast
Earnings Scheduled For October 15, 2014
Making Money With Charles Payne: 11/24/14 (Fox Business)

Credit Suisse upgraded St. Jude Medical (NYSE: STJ) from Neutral to Outperform and raised the price target from $43.00 to $48.00.

Credit Suisse noted, "Since Riata (STJ's recalled defib lead) failure reports began to circulate widely in 8/10, concerns about Durata's reliability (STJ's current defib lead) have weighed on STJ's valuation. While Durata concerns are likely to persist near-term, we came away from STJ's investor day impressed by the company's confidence in Durata and its optimism about the May HRS conference where STJ expects to see multiple favorable Durata studies."

St. Jude Medical closed at $41.17 on Friday.

Latest Ratings for STJ

DateFirmActionFromTo
Nov 2014Cowen & CompanyUpgradesMarket PerformOutperform
Oct 2014Stifel NicolausMaintainsBuy
Oct 2014Canaccord GenuityMaintainsSell

View More Analyst Ratings for STJ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Analyst Ratings

 

Related Articles (STJ)

Around the Web, We're Loving...

Get Benzinga's Newsletters